NexCAR19 is a CAR-T cell therapy indigenously developed and manufactured by ImmunoACT (in association with IIT-Bombay and Tata Memorial Centre)
P. D. Hinduja Hospital, Khar has announced the introduction of CAR-T cell therapy.
NexCAR19 is a CAR-T cell therapy indigenously developed and manufactured by ImmunoACT (in association with IIT-Bombay and Tata Memorial Centre). It is a therapy that modifies immune cells, particularly T-cells, transforming them into potent cancer fighters known as CAR-T cells. This therapy, which is a 2nd generation humanised CAR-T cell therapy, is autologous (patient-specific), and targets the CD19 protein – a biomarker that is overexpressed in certain B-cell cancers.
Gautam Khanna, CEO, P. D. Hinduja Hospital said, “We are proud to be one of the first healthcare institutions in Mumbai to provide our patients with CAR-T cell therapy, a revolutionary new therapeutic option that has the potential to transform the way we treat cancer. The launch of CAR-T cell treatment at P. D. Hinduja Hospital represents a significant milestone and highlights our commitment to providing our patients with the most cutting-edge treatments available, and we hope to make this therapy available to as many patients as possible.”
This therapy is recommended for patients with B-cell lymphomas or B-acute lymphoblastic leukemia who have not responded to traditional therapies such as chemotherapy, resulting in a relapse or recurrence of cancer. Also called a living drug, the therapy gives considerable advantages and involves swift, single infusion treatment, improving the quality of life for many patients at almost one-tenth the cost commercially available worldwide.